Expert Ratings For Relay Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Relay Therapeutics (NASDAQ:RLAY) over the past quarter, with a range of opinions from bullish to bearish. The average 12-month price target has decreased to $21.0 from $22.67. Key analysts have maintained or adjusted their ratings and price targets, reflecting their views on the company's market position and performance.
June 07, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Relay Therapeutics has received mixed analyst ratings over the past quarter, with a new average 12-month price target of $21.0, down from $22.67. Key analysts have maintained or adjusted their ratings, reflecting their views on the company's market position and performance.
The mixed ratings and the decrease in the average price target suggest a neutral short-term impact on the stock. While some analysts remain bullish, others have adjusted their expectations, indicating uncertainty about the company's near-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100